Pulling SEC filings + quote and writing the call…

MOHAWK INDUSTRIES INC
Next earnings Jul 22, 2026 · consensus $2.61 EPS, $2.82B rev
Last earnings +2.6% on 2026-04-30
World's largest flooring maker at trough earnings, trading below book and 0.6x sales — cheap cyclical leveraged to a housing recovery.
Revenue (FY2025) $10.8B · FY2025
The fundamentals carry the rating, but the price is rich (~64% above our fair-value estimate) — a quality-at-a-price call. The case rests on the business, not the entry; patient buyers may wait for a pullback.
Mohawk Industries is the world's largest flooring manufacturer, with operations in 19 countries and sales in ~180, and the stock is a textbook cyclical-trough value situation. FY2025 was weak: revenue was roughly flat at $10.8B (-0.5%), operating income fell 29.4% to $490M, net income dropped 28.1% to $370M, and diluted EPS fell 26.7% to $5.93, with margins compressed to 23.9% gross / 4.5% operating / 4.4% ROE. Management attributes the softness directly to historically low U.S. housing turnover, sluggish new-home construction and weak consumer confidence deferring discretionary remodel spending — cyclical, not structural, headwinds. The earnings history shows the volatility: $1.03B net income in FY2021, near-zero in FY2022, a $449M loss in FY2023, then $515M and $370M in FY2024-FY2025.
The value case rests on a strong balance sheet and depressed valuation. Equity is $8.37B against a market cap of about $6.90B, so the stock trades below book value, at just 0.6x sales and 18.9x trough EPS. Leverage is low (liabilities/equity 0.63x; long-term debt $1.74B against $856M cash, up 28.4%), and the company still generated $1.06B of operating cash flow and bought back $150M of stock. Management cut capex to $440M (about 30% below depreciation) — disciplined capital allocation in a downturn — and restructuring actions since 2022 are expected to deliver roughly $365M of annualized benefits, with another ~$30M of savings pending, positioning operating leverage for when volumes recover.
Is MHK a buy? The one-page verdict, explained →
BUY verdict with defined risk: the short call finances part of the long one; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $11.2B | $11.7B | $11.1B | $10.8B | $10.8B |
| Gross profit | $3.27B | $2.94B | $2.71B | $2.69B | $2.57B |
| Operating income | $1.34B | $244M | -$292M | $694M | $490M |
| Net income | $1.03B | $25.2M | -$449M | $515M | $370M |
| Diluted EPS | $14.94 | $0.39 | -$7.05 | $8.09 | $5.93 |
| Net margin | 9.2% | 0.2% | -4.0% | 4.7% | 3.4% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Sources: SEC EDGAR (CIK 0000851968, latest 10-Q filed 2026-05-01) · EODHD · Proprietary analysis · as of 6/21/2026, 8:56:21 PM.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:56 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 0 open-market buys · 19 sales
| 2026-06-18 | HELEN SUZANNE L Insider | Sell | 3.00K @ $111.27 | $334K |
| 2026-06-18 | HELEN SUZANNE L Insider | Sell | 3.00K @ $113.17 | $340K |
| 2026-06-18 | HELEN SUZANNE L Insider | Sell | 3.00K @ $113.30 | $340K |
| 2026-06-18 | HELEN SUZANNE L Insider | Sell | 3.00K @ $113.98 | $342K |
| 2026-06-18 | HELEN SUZANNE L Insider | Sell | 4.60K @ $113.07 | $520K |
| 2026-06-17 | HELEN SUZANNE L Insider | Sell | 2.00K @ $113.04 | $226K |
| 2026-06-17 | HELEN SUZANNE L Insider | Sell | 3.00K @ $111.17 | $334K |
| 2026-06-16 | HELEN SUZANNE L Insider | Sell | 3.00K @ $112.68 | $338K |
| 2026-06-15 | HELEN SUZANNE L Insider | Sell | 890.00 @ $112.20 | $99.9K |
| 2026-06-15 | LORBERBAUM JEFFREY S CHIEF EXECUTIVE OFFICER | Sell | 2.75K @ $111.26 | $306K |
| 2026-06-15 | LORBERBAUM JEFFREY S CHIEF EXECUTIVE OFFICER | Sell | 1.75K @ $113.37 | $198K |
| 2026-06-12 | HELEN SUZANNE L Insider | Sell | 1.85K @ $108.02 | $200K |
| Two Sigma Investments | 627K sh | $61.7M |
As of each fund’s latest quarterly 13F — a delayed snapshot, not a live position. All tracked funds →
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1194 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.